Cymulate
PrivateLast Round
Series D
Sep 6, 2022
Est. Valuation
$500M
Total Funding Raised
$141M
Company Overview
Cymulate is a cybersecurity company that provides a SaaS-based exposure management and security validation platform to test and improve security resilience.
Sector
Cybersecurity
Verticals
Vulnerability Management, Cloud Security, Threat Intelligence, Compliance & Risk, Zero Trust
Business Model
B2B
Customer Profile
Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cymulate Comparables
Compare Cymulate with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SafeBreach | 94% | |
| Picus Security | 89% | |
| Pentera | 88% |
Cymulate Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 6, 2022 | ||||
| Series C | May 5, 2021 | ||||
| Series B | Nov 26, 2019 | ||||
| Series A | Mar 14, 2019 | ||||
| Seed | Mar 10, 2017 | ||||
Seed | Jun 1, 2016 |
Key People
Founding team and executive leadership
Cymulate Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| One Peak | Series D, Series C |
| Susquehanna International Group | Series D, Seed |
| Vertex Ventures Israel | Series B, Series D, Series C, Series A |
| Dell Technologies Capital | Series B, Series D, Series C, Series A |
| Susquehanna Growth Equity | Series B, Series A, Series D, Series C, Seed |
| Vertex Ventures US | Series A |
| Vertex Holdings | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Presented on hybrid security and four CVEs at Black Hat Asia.
- Mar 3, 2026
Monthly visitors increased 54% MoM.
Recent news
Latest coverage and updates
- launchesAug 25, 2026
Cymulate launches MCP Server and Claude Plugin on Aug 25th '26, enabling customers to access validated exposure intelligence through AI tools, execute assessments, and apply validation findings.
- launchesAug 25, 2026
Cymulate launches MCP Server and Claude Plugin on Aug 25th '26, enabling customers to access validated exposure intelligence directly from the AI tools they use for security tasks and recurring agentic processes.
- partners_withAug 5, 2026
Cymulate plans to partner with BitSight to connect threat intelligence with continuous exposure validation, helping security teams validate defenses, prove security effectiveness, and close validated gaps, as announced in Israel on Aug 5th '26.
Cymulate Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cymulate's valuation, stock price, and market status.
Is Cymulate a public or private company?
Cymulate is a private company.
What is the current stock price of Cymulate?
Cymulate is a private company, so its shares have no public market price. Caplight tracks Cymulate's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cymulate worth (valuation)?
Cymulate's valuation is estimated at $500.0M based on funding round data.
Can I buy Cymulate stock?
Cymulate shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cymulate's last funding round?
Cymulate's most recent funding round was Series D on September 6, 2022.
Who are the main investors in Cymulate?
Key investors in Cymulate include One Peak, Susquehanna International Group, Vertex Ventures Israel, Dell Technologies Capital, Susquehanna Growth Equity.
Will Cymulate IPO soon?
No public IPO plans have been announced for Cymulate.
How can I track Cymulate secondary market activity?
Caplight tracks bids, offers, and trades in Cymulate's shares on secondary markets.